Montanari F. (2015), British Journal of Haematology (Link to abstract)
This is a large single center retrospective analysis of 120 patients with PTLD treated at Columbia University Medical Center between 1990 and 2009. Based on recursive partitioning of this data, a new prognostic score model is suggested using three clinical-pathologic features: Eastern Cooperative Oncology Group (ECOG) score, age and CD20 expression. Using these parameters patients were allocated into 4 risk categories with overall survival as the main outcome. A subgroup of CD20 negative pediatric patients with ECOG scores of 2–4 was identified with particularly low survival. Interestingly, no benefit in overall survival was observed in CD20 positive adults post rituximab treatment compared to a homogeneous group from the pre rituximab era.
* A new prognostic score model for PTLD is suggested but has not yet been validated in a second unrelated cohort.